Day One Biopharmaceuticals, Inc. recently announced an exclusive worldwide licensing agreement and research collaboration with Sprint Bioscience for its cowpox-associated kinase 1 (VRK1) program in an effort to provide additional therapeutic options for brain tumor patients.
VRK1 is a novel target involved in the regulation of cell division and DNA damage repair. Overexpression of VRK1 is associated with poor prognosis in a variety of adult and pediatric cancers, and it has been identified as a synthetic lethal target in tumors deficient in its paralogous homologous protein VRK2. Most high-grade gliomas and high-risk neuroblastomas repress VRK2 gene expression through promoter methylation, which provides a practical way to screen patients with tumors that are sensitive to VRK1 repression.
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of pediatric cancer therapies. The Company's lead drug candidate, toporafenib, is a highly selective oral type II pan-RAF kinase inhibitor that inhibits the growth of tumors harboring BRAF fusions or BRAF V600 mutations with brain penetrance.Tovorafenib has received Breakthrough Therapy designation and Rare Pediatric Disease status from the FDA for the treatment of tumors harboring activating RAF mutations in pediatric low-grade gliomas. The Company's product pipeline also includes pimasertib, an investigational oral, highly selective MEK-1/-2 small molecule inhibitor.
Under the terms of the agreement, Day One will make an upfront payment of $3 million to Sprint Bioscience and reimburse Sprint Bioscience for preclinical research and development expenses. Upon the achievement of certain research, development, regulatory and commercial results, Sprint Bioscience will be eligible to receive additional milestone payments of up to approximately $313 million.Day One expects to complete the filing of a new drug application (NDA) for its pediatric anticancer drug toporafenib in October.
The editorial board of the drug enterprise more than, enterprise strategic cooperation, strong joint,, in addition to can create sustainable social value for the benefit of the masses, for the enterprise, the cooperation between the enterprise can promote the high quality development of the pharmaceutical industry, so as to enhance the enterprise's industry concentration and market competitiveness. As a professional and independent third-party pharmaceutical industry supply and demand trading platform, the pharmaceutical industry investment and transfer platform itself has many years of experience focusing on the pharmaceutical industry services, bringing together the pharmaceutical and health industry in the research project, scientific research results, patented technology, value of approvals, in the operation of the pharmaceutical industry, such as investment and transfer of information resources, in order to promote the industry's exchange of information on pharmaceuticals and to help investors and transferees docking, and to facilitate cooperation and win-win situation between enterprises. It promotes the exchange of pharmaceutical information in the industry, helps investors and transferors to dock, and facilitates win-win cooperation among enterprises.